Introduction {#s2}
============

Since HIV tests became available in the mid-1980s, concerns about human rights have led to heated discussions among those promoting wider testing and those who fear the social consequences of positive diagnoses. In the early years of the epidemic, a degree of "exceptionalism" characterized policies around HIV, whereby public health measures that were considered normal for other diseases, including routine testing, were deemed unacceptable in the case of HIV, because of the potential for stigma and discrimination [@pmed.1001329-Bayer1]. Proponents of wider testing maintained that traditional modes of voluntary counseling and testing (VCT) could not sufficiently expand access to treatment and prevention [@pmed.1001329-DeCock1], but many human rights advocates were reluctant to endorse the routinization of testing or its expansion at health facilities. They argued that the potential benefits did not outweigh the risks, that only client-initiated VCT was acceptable, and that careful scrutiny of consent procedures and practices around confidentiality was necessary [@pmed.1001329-Bayer2]--[@pmed.1001329-Gruskin1]. Despite the wider availability of treatment, there are continuing concerns about expanding testing if consent, confidentiality, and proper care cannot be guaranteed [@pmed.1001329-Bayer1],[@pmed.1001329-Bayer2].

Until recently, the evidence to inform debates around HIV testing was patchy, in part because of the lack of unified criteria to measure outcomes, particularly in sub-Saharan Africa. In addition, studies that examined the shift from client- to provider-initiated testing tended to focus on acceptance rates rather than on actual testing experience [@pmed.1001329-Weiser1]. There have not been systematic examinations of differences in outcomes for VCT compared to provider-initiated testing and counseling (PITC).

In the past few years, growing interest in monitoring HIV testing has led to the formulation of guidelines to ensure that practices around informed consent, confidentiality, and care respect the rights of clients. In 2007, the World Health Organization published a guidance document on PITC, shortly after the US Centers for Disease Control and Prevention had developed their own guidelines, and in 2009, European countries formulated guidelines to define minimum standards of what should be provided everywhere [@pmed.1001329-World1]--[@pmed.1001329-World2] (see also the more recent summaries [@pmed.1001329-World3],[@pmed.1001329-Poljak1]). Despite some variations, these international guidelines represent a useful basis to define a set of outcomes that are measurable across settings.

The MATCH (Multi-Country African Testing and Counseling for HIV) study was designed to conduct systematic comparisons across countries of different ways of providing HIV testing (referred to here as modes of testing). Its overall goals are to investigate the uptake of testing, to analyze differences in the experience of testing across countries and modes of testing, and to assess the implications of these results for policies designed to increase knowledge of HIV status and referral to care. The project formulated a number of specific aims regarding variations in services around testing, in motivations to test, and in the experience of testing and its consequences, as reported by clients and by providers. Different sorts of data were collected, ranging from large surveys of clients using precoded responses (used in this analysis) to qualitative data transcribed from semi-structured interviews with key informants (not used in this analysis). Analyses of MATCH data focus on particular subsets of the data, for example, those pertaining to attitudes towards testing, the extent of stigma, or the frequency of disclosure of HIV status. In this analysis, we focus on services related to testing and examine the extent to which consent, confidentiality, and referral to care vary across modes of testing, namely VCT and PITC.

MATCH was conducted in four countries---Burkina Faso, Kenya, Malawi, and Uganda---that exemplify different approaches to the provision of services. In all four countries, multiple government- and donor-supported initiatives have been implemented, and, increasingly, testing is conducted at health facilities. But testing practices reflect the countries\' different histories with HIV testing and foreign aid, and there are differences in the pace of increase (somewhat slower in Burkina Faso), in the scale of the resources invested (larger in Kenya and Uganda), in the role of VCT (which still represents an important mode of provision in Burkina Faso and Uganda), and in the relative roles of governments and nongovernment organizations. All four countries face similar challenges with the expansion of testing: insufficient resources, infrastructure, and adequately trained staff; limited public awareness about the risks of HIV; and difficulties with referral and follow-up. But while fears of coercion and breaches of confidentiality are frequently invoked in the literature, it is unclear whether these differ depending on how testing is provided, and how clients feel regarding their experiences with different modes of testing.

This paper analyzes respondents\' reports regarding consent, confidentiality, and referral, to assess whether these outcomes differ systematically by mode of testing. Specifically, we assess whether eight outcome measures related to the completeness and quality of services---including the adequacy of pre- and post-test counseling, clients\' consent to test, confidentiality, satisfactory interactions with providers, and referral for those HIV positive---differ between provider-initiated and client-initiated modes of testing. The null hypothesis, that there are no significant differences, would suggest that inadequate outcomes are not more likely when testing is scaled up at health facilities.

Methods {#s3}
=======

Ethics Statement {#s3a}
----------------

The study was approved by the Ethics Review Committee of the World Health Organization and by an Institutional Review Board (IRB) in each of the four countries (Burkina Faso\'s Comité d\'Ethique pour la Recherche en Santé of the Ministries of Health and Higher Education, Kenyatta National Hospital\'s IRB in Kenya, the National Health Sciences Research Committee of the Ministry of Health and Population in Malawi, and the IRB of Makerere University and the National Council for Science and Technology in Uganda). Informed consent was obtained from all respondents who were invited to participate in the study. In Burkina Faso and Uganda, consent was in writing for virtually all respondents, except for a few illiterate respondents, who provided a thumbprint; in Malawi and Kenya, a greater proportion of respondents gave oral consent, consistent with local practices and, in the case of Malawi, because of higher illiteracy. Because the proportion of oral consent was relatively high in Kenya (24%), special permission to use the data from those interviews was obtained from the IRB. No identifying information was collected as part of the study dataset.

Study Design and Sample {#s3b}
-----------------------

The core component of the MATCH study is a client survey, conducted in 2008--2009 at health facilities. It was designed to represent users of health facilities in the capital city and one province in each country, and to include individuals who had tested and others who had not tested for HIV. In each country, the research team, which comprised individuals knowledgeable about HIV testing, drew up a list of health facilities or services within large facilities that provided HIV testing, and facilities or services known not to provide HIV testing. The list of facilities for testers included the major providers of testing services and different types of facilities, namely, stand-alone facilities for VCT and integrated facilities where testing was provided along with prenatal care, tuberculosis treatment, or general medical care. Non-testers were recruited at medical facilities or services where HIV testing was not provided. Testing status was ascertained for all respondents. Other components of the MATCH study, not incorporated into this analysis, include smaller surveys of clients tested at home or during campaigns, interviews with providers, and semi-structured interviews with selected clients and providers.

About 20 facilities or services within larger facilities were selected for inclusion in each country. Adult clients (aged 18 y and over) who were present at the selected facilities on the appointed days were invited to participate in the study. All respondents who agreed to discuss their experience with testing or not testing for HIV were included. Response rates are estimated at 80% in Burkina Faso and 90% in Malawi and Uganda; the figure for Kenya is considerably lower, at about one-half, reflecting the difficult political situation prevailing in 2008, which translated into poor security, reluctance to participate, and cancelling or aborting of interviews.

The instrument used in the client survey included closed- and open-ended questions about socio-demographic information; attitudes towards HIV testing and counseling; testing status; for those previously tested, a checklist on services received during pre- and post-test meetings and follow-up care; and interactions with providers and experiences before, during, and after testing, including disclosure and stigma. The interview was piloted in the four countries and revised in light of field experience to ensure that the questions were understood and the sequence of questions was adequate. Interviews lasted approximately 30 min.

A total of 3,659 respondents were interviewed at the selected facilities in the four countries. Because we were interested in recent testing experience across different modes of testing, this analysis focuses on respondents who reported testing at different sorts of facilities in the 2 y preceding the survey. We excluded non-testers (1,088); testers who reported testing before 2007 or who were missing information on test date or testing status (385); those missing data on place of test or whose place of test could not be categorized, for example, if they tested abroad (34); and those missing information on covariates (36). Thus, the analysis includes 2,116 respondents tested at different types of facilities in 2007 or later. Each outcome was analyzed using a complete case method. Denominators are not the same for all outcome measures, for example, respondents who did not meet with a counselor before their test were not eligible to answer questions about the quality of pre-test counseling. The final sample values are found in [Table 1](#pmed-1001329-t001){ref-type="table"}. The analysis is stratified by country, because differences in policy environments and in the implementation of HIV testing made it plausible that there would be different associations in the four countries between test modes and the outcome measures in which we were interested.

10.1371/journal.pmed.1001329.t001

###### Percent respondents reporting on outcome measures of HIV testing, by country and mode of testing.

![](pmed.1001329.t001){#pmed-1001329-t001-1}

  Country                                   Outcome Measure                        Integrated (Percent)   VCT (Percent)   PMTCT (Percent)   Total (*n*)   Total (Percent Yes)   χ2(2)                  *p*-Value
  ------------------- ----------------------------------------------------------- ---------------------- --------------- ----------------- ------------- --------------------- ------- -----------------------------------------
  **All countries**                  Pre-test: meet with counselor                         83.3               95.3             92.3            1,875              89            66.18                   \<0.001
                                       Pre-test index: all items                           78.6               73.1             72.3            1,410             75.4           8.38                     0.015
                                       Consent index: all items                            89.7               83.4             82.9            1,611             86.1           16.51   \<0.001[b](#nt102){ref-type="table-fn"}
                                      Post-test: received results                          98.6                100              99             1,997             99.1           9.04                     0.011
                                      Post-test index: all items                           58.7               35.8              59             1,015             51.5           90.25                   \<0.001
                                   Confidentiality index: all items                        81.6                77              77.6            1,451             79.2           5.34                     0.069
                       Referral index[a](#nt101){ref-type="table-fn"}: all items           73.7               66.2             63.3             393              70.6           4.52                     0.105
                                     Satisfaction index: all items                         80.2               79.9              83             1,647             80.7           1.78                     0.411
  **Burkina Faso**                   Pre-test: meet with counselor                         67.4               96.3             96.2             538              88.8           86.24   \<0.001[b](#nt102){ref-type="table-fn"}
                                       Pre-test index: all items                           45.7               62.4             40.2             476              54.4           18.43   \<0.001[b](#nt102){ref-type="table-fn"}
                                       Consent index: all items                            77.2               74.8             83.3             476              77.1           3.07                     0.215
                                      Post-test: received results                          95.6                100              100             537              98.9           17.72   \<0.001[b](#nt102){ref-type="table-fn"}
                                      Post-test index: all items                           7.8                15.1             14.2             525              13.1           4.28                     0.118
                                   Confidentiality index: all items                         75                77.4             64.4             463              74.1           6.56                     0.038
                       Referral index[a](#nt101){ref-type="table-fn"}: all items           63.8               50.8             83.3             114              57.9           3.52                     0.172
                                     Satisfaction index: all items                         62.1               77.0             77.1             516              73.4           10.79    0.005[b](#nt102){ref-type="table-fn"}
  **Kenya**                          Pre-test: meet with counselor                          97                 97              92.4             376               96            3.39                     0.183
                                       Pre-test index: all items                           82.8                75              82.2             361               82            1.18                     0.555
                                       Consent index: all items                            95.3               93.8             90.4             361              94.2           2.50                     0.286
                                      Post-test: received results                          99.2                100              100             376              92.4           0.86                     0.649
                                      Post-test index: all items                           79.1               68.8             82.1             363              78.8           2.44                     0.296
                                   Confidentiality index: all items                        78.8               72.7              74              356              77.2           1.17                     0.557
                       Referral index[a](#nt101){ref-type="table-fn"}: all items           81.4               77.8             87.5             130              81.5           0.27                     0.872
                                     Satisfaction index: all items                         83.1               87.5             88.6             366              84.7           1.60                     0.448
  **Malawi**                         Pre-test: meet with counselor                          87                97.7             91.4             529               89            5.49                     0.064
                                       Pre-test index: all items                           92.1               90.5              89              471              91.1           1.06                     0.588
                                       Consent index: all items                            94.4               88.1             88.2             471              92.1           5.76                     0.056
                                      Post-test: received results                          99.4                100             99.3             524              93.3           0.30                     0.860
                                      Post-test index: all items                           71.2               53.5             75.2             517              70.8           7.53     0.023[b](#nt102){ref-type="table-fn"}
                                   Confidentiality index: all items                        94.9               85.7              92              462              93.3           5.43                     0.066
                       Referral index[a](#nt101){ref-type="table-fn"}: all items           66.2               57.1             56.3             175               64            1.26                     0.533
                                     Satisfaction index: all items                         95.3               90.7             93.5             520              94.4           1.84                     0.398
  **Uganda**                         Pre-test: meet with counselor                         72.7               93.9             89.4             664              85.1           51.97   \<0.001[b](#nt102){ref-type="table-fn"}
                                       Pre-test index: all items                           67.2               80.8             77.4             562              75.8           11.62    0.003[b](#nt102){ref-type="table-fn"}
                                       Consent index: all items                            80.6               89.8             67.5             563              83.5           25.02   \<0.001[b](#nt102){ref-type="table-fn"}
                                      Post-test: received results                          98.2                100             96.6             578              98.8           7.23     0.027[b](#nt102){ref-type="table-fn"}
                                      Post-test index: all items                           45.9               52.1             67.4             565               52            11.48    0.003[b](#nt102){ref-type="table-fn"}
                                   Confidentiality index: all items                        67.0               75.8             75.3             552              72.8           4.61                     0.100
                       Referral index[a](#nt101){ref-type="table-fn"}: all items           86.0               78.4             57.1             138               79            5.52                     0.063
                                     Satisfaction index: all items                         65.0               80.4             68.5             640               73            17.29   \<0.001[b](#nt102){ref-type="table-fn"}

Includes only HIV-positive respondents.

Remains significantly less than 0.05 after correction for false discovery rate.

This analysis is designed to assess the extent to which respondents\' experiences with testing are consistent with prevalent standards for the quality and completeness of the services to be provided along with HIV testing. We draw on data collected in response to questions and checklists regarding respondents\' testing experience, including the information, advice, and referral that were provided during pre- and post-test counseling, interaction with providers, and the extent to which clients\' rights were protected by practices regarding consent and confidentiality. We assess whether there are differences in these responses for clients tested at different types of testing facilities, adjusting for respondents\' socioeconomic characteristics and for the clustering of responses in interview facilities.

Outcome Measures {#s3c}
----------------

Primary outcomes in this study included eight measures of the quality and completeness of the testing process for each respondent. Unified guidelines for testing were not available for the four countries at the time the study was designed, but we drew on the documents issued by the World Health Organization and the US Centers for Disease Control and Prevention [@pmed.1001329-World1],[@pmed.1001329-US1] to define the elements that were generally thought to ensure adequate care and to protect individuals\' rights during and after HIV testing.

The "3 Cs" framework refers to consent, confidentiality, and counseling as essential elements in HIV testing [@pmed.1001329-Joint1]. In view of discussions regarding how much pre-test counseling is necessary, and the need to tailor post-test counseling to the test results [@pmed.1001329-World1],[@pmed.1001329-US1],[@pmed.1001329-Cohan1], we examined the adequacy of pre- and post-test counseling separately. Thus, pre- and post-test counseling, consent, and confidentiality are the first four outcomes. We used clients\' reports on their interactions with providers---whether they thought the information provided was sufficient, whether they were well treated, and whether they found the meeting useful---to create a fifth outcome measure that we referred to as satisfaction. The sixth outcome measure, referral, captures the extent to which testing was linked to further care for HIV-positive respondents. In addition, because pre-test measures depend on having had a pre-test meeting and post-test measures on receiving results, we also analyzed the likelihood of these two additional outcome measures where appropriate, for a total of eight outcome measures.

We used respondents\' responses to specific questions in the interview to create an index for each of these outcome measures. Because we wanted to assess whether each required element was present, we gave equal importance to the items that defined each index, and coded the index as complete if all items were present, and as incomplete if any was absent. The outcome measures and the individual items that make up each index are summarized in [Box 1](#pmed-1001329-box002){ref-type="sec"}.

### Box 1. Outcome Measures Regarding Pre- and Post-Test Counseling and Referral {#s3c1a}

#### Indices of Pre- and Post-Test Counseling and Referral\* {#s3c1a1}

**1. Pre-test counseling index**

Whether the provider:

-   Explained how HIV is transmitted

-   Explained the meaning of positive and negative results

-   Gave time to ask questions

**2. Post-test counseling index**

Whether the provider:

-   Explained the meaning of the results

-   Gave advice on prevention

-   Advised discussing test results with significant others

-   Advised partner referral

-   Gave time to ask questions

**3. Consent index**

Whether the provider:

-   Asked if respondent agreed to test

-   Explained that respondent had a choice to accept or refuse

**4. Confidentiality index**

-   Whether provider explained that results would not be shared

-   Whether respondent believed results had been protected

**5. Satisfaction with post-test counseling index**

Whether respondent:

-   Thought s/he received sufficient information

-   Thought s/he was well treated

-   Thought the meeting was useful

**6. Referral index (only for HIV-positive individuals)**

Whether respondent:

-   Was referred for care during post-test counseling

-   Was ever prescribed medications

#### Additional Outcome Measures {#s3c1a2}

**7. Pre-test meeting**

Whether the respondent had a pre-test meeting

**8. Post-test results received**

Whether the respondent received results in post-test meeting

\*Based on the questions as phrased in the questionnaire.

Independent Variables {#s3d}
---------------------

The key independent variable used is the mode of testing. The different types of testing facilities were grouped into three modes of testing: (1) integrated testing, which included hospitals and medical facilities where provider-initiated and client-initiated testing were both provided, along with medical services; (2) stand-alone VCT; (3) prevention of mother-to-child transmission (PMTCT) testing, which included antenatal clinics and other facilities offering care to pregnant women; additionally, all women who reported testing in integrated testing facilities because of pregnancy were coded as PMTCT testers.

Other covariates that may have influenced clients\' experiences of testing and were adjusted for in the analyses included age, education, and wealth. Age was self-reported and measured in years. Education was specified as no schooling, incomplete or completed primary education, or some secondary education. We developed a country-specific wealth index using principal components analysis. The wealth index methodology is based on the Filmer-Pritchett wealth score methodology developed for Demographic and Health Surveys [@pmed.1001329-Filmer1], which incorporates dichotomous variables into a wealth score using factor analysis. This method has been widely used in international health surveys and has been established as a reliable proxy for household wealth. Respondents\' household assets (television, electric or gas stove, telephone, land, animals) and amenities (tap water, flush toilet, electricity) were converted into *z*-scores, and factor loadings for a single wealth factor were calculated. Values of the indicator variables were multiplied by the factor loadings to obtain a wealth score for each respondent. Within each country, respondents were grouped into quartiles by wealth score.

Analysis Plan {#s3e}
-------------

We estimated the unadjusted and adjusted effects of mode of testing on the eight outcome measures. The effect of mode of testing on referral to subsequent care is estimated for HIV-positive respondents only. Unadjusted associations were tested using chi-squared tests, and Fisher\'s exact tests of significance were also used in analyses with cell sizes of five or fewer respondents. In many cases, more than 10% of respondents in each group had tested for HIV, so odds ratios estimated using logistic regression analysis would not provide a reasonable estimate of the relative prevalence of testing. Consequently, to estimate adjusted associations between mode of testing and index scores we used a modified Poisson regression analysis with robust standard errors [@pmed.1001329-Zou1]. We report 95% confidence intervals for all parameters and exact *p*-values from Wald tests of significance for all tests where *p*≥0.001. Given the number of comparisons, our analyses also adjusted for false discovery rate using the Benjamini, Krieger, and Yekutieli step-up adjustment method [@pmed.1001329-Newson1], as implemented using the smileplot add-on to Stata 10 [@pmed.1001329-Benjamini1] and an unadjusted *p*-value of 0.05.

All regression analyses estimated the effect of mode of testing, and we compared VCT and PMTCT to integrated testing as the reference category. Regression analyses were adjusted for country, using a fixed effect (fixed effect parameters and constants not shown), and standard errors were adjusted for clustering of responses at the interview facility, using a generalized estimating equation. All analyses were completed in Stata, release SE 10.1 [@pmed.1001329-StataCorp1]. This report adheres to STROBE guidelines (see [Text S1](#pmed.1001329.s002){ref-type="supplementary-material"}).

Results {#s4}
=======

The distribution of respondents by testing mode differs across countries. More respondents tested at stand-alone VCT sites than at integrated sites in Burkina Faso (55% \[293/537\] and 26% \[138/537\], respectively) and Uganda (47% \[315/664\] and 38% \[255/664\]), while more tested at integrated sites than at stand-alone VCT sites in Malawi (65% \[348/533\] and 8% \[43/533\], respectively) and Kenya (70% \[268/382\] and 9% \[34/382\]). PMTCT testers ranged from 14% (94/664) in Uganda to 27% (142/533) in Malawi. (Detailed frequencies of respondents\' age, sex, educational attainment, and wealth score quartiles, by country and mode of testing, are presented in [Table S1](#pmed.1001329.s001){ref-type="supplementary-material"}.)

[Table 1](#pmed-1001329-t001){ref-type="table"} presents the frequencies of respondents\' reports on the eight outcome measures across all countries and for each country.

Across all countries, respondents in integrated testing were less likely to meet with a counselor before their HIV test (83% compared with 95% of VCT testers; *p\<*0.001), but those who did meet with a counselor were more likely to have completed consent procedures (89% compared with 83% among VCT testers; *p\<*0.001) and pre-test counseling (78% compared with 73% among VCT testers; *p = *0.015). Both integrated and PMTCT testers were more likely to receive complete post-test counseling than were VCT testers (59% among both PMTCT and integrated testers compared with 36% among VCT testers; *p*\<0.001). Differences among the three groups in proportion referred to care, proportion satisfied with their post-test counseling, and proportion believing that confidentiality had been ensured were not significant.

Examining the unadjusted associations between testing mode and outcome measures by country reveals some notable differences, as shown in [Table 1](#pmed-1001329-t001){ref-type="table"}. In Burkina Faso, integrated testers were significantly less likely to meet with a counselor before their test (67% compared with 96% among VCT testers; *p*\<0.001), to have a complete pre-test index (46% compared with 62% among VCT testers; *p*\<0.001), and to be satisfied with post-test counseling (62% compared with 77% of VCT testers and 77% of PMTCT testers). In Uganda, integrated testers were less likely to meet with a counselor (73% compared with 94% among VCT testers; *p\<*0.001), to have complete pre-test counseling (67% compared with 81% among VCT testers and 77% among PMTCT testers; *p = *0.003), to have complete post-test counseling (46% compared with 52% among VCT testers and 67% among PMTCT testers; *p = *0.003), and to be satisfied with post-test counseling (65% compared with 80% among VCT testers and 69% among PMTCT testers; *p\<*0.001). In Malawi, VCT testers were less likely to receive full post-test counseling than PMTCT or integrated testers (54% of VCT testers compared with 71% of integrated testers and 75% of PMTCT testers; *p = *0.023). In Kenya there were no significant differences across testing modes.

[Table 2](#pmed-1001329-t002){ref-type="table"} presents the effects of mode of testing on the eight outcome measures, after adjustment for respondent age, sex, educational attainment, and wealth. In Burkina Faso, satisfaction with post-test counseling remained significantly higher among VCT testers than among integrated testers; the adjusted prevalence ratio (APR) comparing VCT testers to integrated testers was 1.28 (95% CI: 1.10--1.48). In Uganda, respondents testing in stand-alone VCT sites were significantly more likely to meet with a counselor (APR: 1.25; 95% CI: 1.04--1.51), to have completed confidentiality procedures (APR: 1.13; 95% CI: 1.04--1.23), and to be satisfied with their post-test counseling experience (APR: 1.23; 95% CI: 1.10--1.37), while HIV-positive PMTCT testers were significantly less likely to receive referrals for additional care (APR: 0.71, 95% CI: 0.57--0.89). In Malawi, respondents testing in stand-alone VCT sites were significantly more likely to meet with a counselor before testing (APR: 1.11; 95% CI: 1.05--1.18).

10.1371/journal.pmed.1001329.t002

###### Prevalence ratios for outcome measures, by country and mode of testing.

![](pmed.1001329.t002){#pmed-1001329-t002-2}

  Outcome Measure                                                  Adjusted Prevalence Ratio (95% CI)                                                                                                
  -------------------------------------------------------------- -------------------------------------- -------------------------------------- -------------- -------------------------------------- --------------------------------------
  **Pre-test meeting**                                                                                                                                                                               
  Integrated testing                                                              1.00                                   1.00                       1.00                       1.00                                   1.00
  Stand-alone VCT                                                 1.22[a](#nt104){ref-type="table-fn"}                   1.45                       0.90       1.11[a](#nt104){ref-type="table-fn"}                   1.25
                                                                              (1.07--1.38)                           (0.94--2.22)               (0.72--1.12)               (1.05--1.18)                           (1.04--1.51)
  PMTCT                                                                           1.09                                   1.41                       0.97                       1.03                                   1.17
                                                                              (1.00--1.20)                           (0.93--2.13)               (0.85--1.10)               (0.96--1.09)                           (0.93--1.47)
  **Pre-test index complete**                                                                                                                                                                        
  Integrated testing                                                              1.00                                   1.00                       1.00                       1.00                                   1.00
  Stand-alone VCT                                                                 1.15                                   1.34                       0.90                       0.97                                   1.18
                                                                              (0.99--1.33)                           (0.86--2.10)               (0.72--1.12)               (0.85--1.10)                           (0.97--1.44)
  PMTCT                                                                           0.98                                   0.88                       0.97                       0.96                                   1.15
                                                                              (0.88--1.09)                           (0.59--1.31)               (0.85--1.10)               (0.87--1.06)                           (0.91--1.45)
  **Consent index complete**                                                                                                                                                                         
  Integrated testing                                                              1.00                                   1.00                       1.00                       1.00                                   1.00
  Stand-alone VCT                                                                 1.03                                   1.01                       1.00                       0.94                                   1.1
                                                                              (0.95--1.12)                           (0.82--1.24)               (0.93--1.08)               (0.88--1.01)                           (0.96--1.27)
  PMTCT                                                                           0.95                                   1.08                       0.94                       0.93                                   0.86
                                                                              (0.89--1.02)                           (0.89--1.31)               (0.82--1.09)               (0.87--1.00)                           (0.66--1.11)
  **Post-test results received**                                                                                                                                                                     
  Integrated testing                                                              1.00                                   1.00                       1.00                       1.00                                   1.00
  Stand-alone VCT                                                                 1.02                                   1.05                       1.00                       1.01                                   1.02
                                                                              (1.00--1.04)                           (0.99--1.10)               (1.00--1.01)               (1.00--1.03)                           (1.00--1.04)
  PMTCT                                                                           1.00                                   1.04                       1.00                       0.99                                   0.98
                                                                              (0.99--1.01)                           (0.99--1.08)               (0.99--1.00)               (0.98--1.01)                           (0.95--1.02)
  **Post-test index complete**                                                                                                                                                                       
  Integrated testing                                                              1.00                                   1.00                       1.00                       1.00                                   1.00
  Stand-alone VCT                                                                 1.00                                   1.93                       0.91                       0.78                                   1.05
                                                                              (0.83--1.20)                           (0.90--4.10)               (0.69--1.21)               (0.59--1.03)                           (0.86--1.28)
  PMTCT                                                                           1.09                                   1.87                       1.04                       1.00                                   1.40
                                                                              (0.94--1.27)                           (0.83--4.24)               (0.91--1.20)               (0.85--1.17)                           (1.01--1.94)
  **Confidentiality index complete**                                                                                                                                                                 
  Integrated testing                                                              1.00                                   1.00                       1.00                       1.00                                   1.00
  Stand-alone VCT                                                                 1.04                                   1.02                       0.99                       0.91                   1.13[a](#nt104){ref-type="table-fn"}
                                                                              (0.97--1.11)                           (0.90--1.15)               (0.82--1.18)               (0.79--1.05)                           (1.04--1.23)
  PMTCT                                                                           0.97                                   0.88                       0.94                       0.97                                   1.14
                                                                              (0.90--1.06)                           (0.76--1.02)               (0.71--1.26)               (0.91--1.03)                           (0.96--1.36)
  **Referral index complete** [b](#nt105){ref-type="table-fn"}                                                                                                                                       
  Integrated testing                                                              1.00                                   1.00                       1.00                       1.00                                   1.00
  Stand-alone VCT                                                                 0.87                                   0.76                       0.90                       0.84                                   0.91
                                                                              (0.74--1.02)                           (0.50--1.16)               (0.78--1.04)               (0.57--1.22)                           (0.78--1.07)
  PMTCT                                                                           0.89                                   1.56                       0.88                       0.89                   0.71[a](#nt104){ref-type="table-fn"}
                                                                              (0.73--1.08)                           (0.87--2.78)               (0.64--1.20)               (0.62--1.26)                           (0.57--0.89)
  **Satisfaction index complete**                                                                                                                                                                    
  Integrated testing                                                              1.00                                   1.00                       1.00                       1.00                                   1.00
  Stand-alone VCT                                                 1.15[a](#nt104){ref-type="table-fn"}   1.28[a](#nt104){ref-type="table-fn"}       1.02                       0.97                   1.23[a](#nt104){ref-type="table-fn"}
                                                                              (1.06--1.25)                           (1.10--1.48)               (0.87--1.21)               (0.88--1.06)                           (1.10--1.37)
  PMTCT                                                                           1.05                                   1.19                       1.06                       0.97                                   1.07
                                                                              (0.98--1.13)                           (1.03--1.38)               (0.92--1.22)               (0.92--1.03)                           (0.80--1.43)

All models adjusted for respondent sex, age (in years), educational attainment, and wealth index, and adjusted for clustered sampling using a generalized estimating equation. All countries model also adjusted for country using fixed effect.

*p*-Value remains significantly less than 0.05 after correction for false discovery rate.

Includes only HIV-positive respondents.

Analyses of the pooled data across countries show a higher likelihood of a pre-test meeting for VCT (APR: 1.22; 95% CI: 1.07--1.38) compared to integrated testing, and higher satisfaction for VCT compared to integrated testing (APR: 1.15; 95% CI: 1.06--1.25). Other differences were not statistically significant.

Discussion {#s5}
==========

First, a major result of this analysis is that across all countries and modes of testing, high percentages of clients reported having received the services around testing that are considered important in most guidelines. As shown in [Table 1](#pmed-1001329-t001){ref-type="table"}, across the four countries, 89% reported having a pre-test meeting, and more than 75% reported a complete pre-test index. Consent, confidentiality, and overall satisfaction indices were high, at 86%, 79%, and 81%, respectively. Provision of post-test services was generally lower: though 99% received their results, just over half reported a complete post-test index, and 71% of HIV-positive respondents reported a complete referral index. This suggests that there is still a good deal of room for improvement to provide advice and referral after HIV testing, but that services around testing do not appear to be associated with major breaches of autonomy or privacy. When we compared reports by HIV-positive and HIV-negative respondents, we found them to be similar, and where they differed, HIV-positive respondents reported more favorably on the services received, which does not support the notion that HIV-positive individuals receive worse services due to stigma.

A second major result of this analysis is that there were some significant associations between outcome measures and modes of testing, but differences across modes of testing were not consistent with the notion that one mode of testing performs better than the others. As shown in [Tables 1](#pmed-1001329-t001){ref-type="table"} and [2](#pmed-1001329-t002){ref-type="table"}, unadjusted analyses indicate somewhat more favorable reports at integrated testing sites on a few outcome measures, while analyses adjusting for covariates and clustering of facilities show slightly higher likelihood of better outcomes for VCT. In general, the results do not support the notion that testing at integrated health facilities functions less adequately than at stand-alone VCT sites.

Taken together, these results suggest that the rights of clients, particularly regarding informed consent and confidentiality, can be protected even as testing is scaled up at health facilities. Some studies have suggested that consent and confidentiality may be jeopardized by inadequate facilities and procedures, poor counseling, or the power differential between providers and patients [@pmed.1001329-Rennie1]--[@pmed.1001329-Turan1], while other studies have documented high acceptability and improved referral, with no reduction in the utilization of health services when testing is routinized [@pmed.1001329-Weiser1],[@pmed.1001329-Cockcroft1]--[@pmed.1001329-Perez1]. The results of this analysis are consistent with studies showing that routine testing is compatible with ethical practices [@pmed.1001329-Leon1],[@pmed.1001329-NgongoBahati1], and this should provide some reassurance about the possibility of scaling up HIV testing through PITC without compromising individual protection.

The association of VCT with more positive outcome measures than integrated or PMTCT testing in Uganda---specifically pre- and post-test counseling, receiving results, and satisfaction---can be attributed to the role of nongovernment organizations, which mobilized early on, when VCT was the only mode of provision, to encourage testing, increase awareness, and fight stigma and discrimination. The less favorable outcomes for pre- and post-test counseling in Burkina Faso may be attributable to the more recent initiation of PITC in the country, which had, for a long time, relied on VCT provided via freestanding facilities and national campaigns. PITC facilities are comparatively less resourced in Burkina Faso, and the guidelines in place at the time of the survey did not recommend all of the post-test items that we included in our indices. Instead, the guidelines in Burkina Faso referred to explaining the meaning of results, providing advice on prevention, and answering questions. When measured against more demanding standards, testing services fell short. These results underscore the need to clarify and harmonize guidelines on testing and counseling and to support their implementation.

The data were collected in 2008--2009, at an important time for the scale-up of HIV testing programs. In the countries where the study was conducted, as well as globally, 2006--2007 was a turning point for the increased availability of treatment, the formulation of guidelines, and the implementation of programs to increase knowledge of HIV status. The results reflect the scale-up of these efforts and are likely indicative of subsequent trends.

The generally favorable outcomes that are documented in this study suggest that it is possible to expand client- and provider-initiated testing while protecting patients\' rights. This should not be surprising. The standards defined by guidelines on testing, such as informing clients, obtaining consent, and providing information, are not especially exacting, and can be achieved in most settings. Other studies, such as in the United States [@pmed.1001329-Rahangdale1],[@pmed.1001329-Podhurst1] and in Egypt [@pmed.1001329-Kabbash1], have reported similarly high levels of service provision ad satisfaction.

It is possible that the high values we found in reported measures of satisfaction result in part from a contrast with clients\' general experience with other health services, which tends to be suboptimal, so that, by comparison, the quality HIV testing services appears to be satisfactory. It is also possible that because respondents were interviewed at health facilities, they may have felt that they should not appear ungrateful for the services they receive, and hence may have given more favorable answers. In order to assess the extent of such social desirability bias, we conducted a sensitivity analysis comparing outcomes among respondents who tested at facilities where interviews were conducted and those who reported testing at facilities not included in the MATCH project. We found that outcomes among respondents tested at MATCH facilities tend to be similar to, or less positive than, those who did not test at MATCH facilities, suggesting that the facility environment did not substantially influence respondents\' reports on the care they received.

Other studies in Kenya and Malawi have found that counseling may be neglected when testing is scaled up, and that clients may perceive testing as compulsory [@pmed.1001329-Njeru1],[@pmed.1001329-Angotti1]. Qualitative data such as were used in these studies are important complements to surveys. They provide insights into potential gaps in the functioning of services, highlighting research questions regarding counseling and consent for further investigation and suggesting areas for improvement. Analyses are underway on the texts transcribed from responses to open-ended questions in the MATCH survey, and from the semi-structured interviews carried out in parallel with the survey. The texts provide a complementary way to assess clients\' views, and the analyses should yield more detailed insights into the reasons for clients\' positive or negative evaluations of their testing experiences.

There are limitations to this study, including the fact that the outcome measures may not account for important social, cultural, and health service variations. Our measures of referral and medication use do not include specific details, and hence provide only a rough measure of referral. In addition, our analysis distinguishes modes of testing as discussed in the literature, and compares VCT and PITC (including integrated and PMTCT testing), but the reality of services on the ground is complex, and the boundaries among types of testing facilities are not always strict. It is also possible that the lack of significant associations between testing mode and outcomes at the level of individual countries reflects the smaller numbers of respondents in some of the categories of testing, and that larger samples may have been able to detect more associations.

A further limitation comes from using a sample of convenience, based on systematic rather than random selection, and hence not necessarily representative. This strategy was deemed to be appropriate, since the goal was to compare testing experiences across modes of testing. MATCH respondents are more urban, educated, and wealthy than respondents to national surveys---except in Malawi, where they are similar [@pmed.1001329-Uganda1]--[@pmed.1001329-Institut1]. This is not surprising, since users of health facilities tend to have higher socioeconomic status than the general population. Thus, there are reasons to believe that these results are not gross overestimates and that they reflect the reality of testing in the selected areas.

A strength of this study is that it used the same outcome measures and methodology across sites. Hence, results can be compared across countries to address policy questions about modes of testing. While there are considerable differences, both within and among countries, in the structural factors that define health services and accessibility and the meanings attached to testing, the motivations behind it, and its consequences, there is a degree of consistency in the results that likely reflects the state of services around testing in these different settings.

Conclusion {#s5a}
----------

Despite variations within and across countries in the outcome measures for pre- and post-test counseling, consent, confidentiality, referral, and satisfaction, respondents\' reports indicate that the frequencies of positive responses on these measures are generally high, suggesting that overall, people testing for HIV do not appear to experience adverse outcomes such as coercion or breaches of confidentiality, and that the majority of people who are tested are satisfied with the services they receive.

The fact that we found few consistent associations between mode of testing and outcome measures is also encouraging. Provider-initiated modes of testing (integrated medical testing and PMTCT testing) were not more likely to be associated with less favorable outcome measures than VCT. These results should provide some reassurance that the efforts to provide HIV testing in different countries through different approaches can help improve knowledge of HIV status and referral to appropriate care.
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APR

:   adjusted prevalence ratio

IRB

:   Institutional Review Board

PITC

:   provider-initiated testing and counseling

PMTCT

:   prevention of mother-to-child transmission

VCT

:   voluntary counseling and testing
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